How to buy ORIC Pharmaceuticals stock | $16.23

ORIC Pharmaceuticals Inc is a biotechnology business based in the US. ORIC Pharmaceuticals shares (ORIC) are listed on the NASDAQ and all prices are listed in US Dollars. ORIC Pharmaceuticals employs 70 staff and has a market cap (total outstanding shares value) of 0.00.

ORIC Pharmaceuticals stock price (NASDAQ: ORIC)

Use our graph to track the performance of ORIC stocks over time.

ORIC Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-09.

Latest market close	$16.23
52-week range	$15.67 - $40.81
50-day moving average	$22.08
200-day moving average	$21.09
Wall St. target price	$40.86
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.66

Buy ORIC Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ORIC Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ORIC Pharmaceuticals price performance over time

Historical closes compared with the close of $16.23 from 2021-10-15

1 week (2021-10-08)	4.98%
1 month (2021-09-16)	-33.94%
3 months (2021-07-16)	-16.56%
6 months (2021-04-16)	-23.91%

1 year (2020-10-16)	-34.00%
2 years (2019-10-12)	N/A
3 years (2018-10-12)	N/A
5 years (2016-10-12)	N/A

ORIC Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-17.74%
Return on equity TTM	-40.27%
Profit margin	0%
Book value	$7.04
Market capitalisation	$607.9 million

TTM: trailing 12 months

Shorting ORIC Pharmaceuticals shares

There are currently 3.1 million ORIC Pharmaceuticals shares held short by investors – that's known as ORIC Pharmaceuticals's "short interest". This figure is 4.9% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting ORIC Pharmaceuticals shares can be evaluated.

ORIC Pharmaceuticals's "short interest ratio" (SIR)

ORIC Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ORIC Pharmaceuticals shares currently shorted divided by the average quantity of ORIC Pharmaceuticals shares traded daily (recently around 151409.81262327). ORIC Pharmaceuticals's SIR currently stands at 20.28. In other words for every 100,000 ORIC Pharmaceuticals shares traded daily on the market, roughly 20280 shares are currently held short.

However ORIC Pharmaceuticals's short interest can also be evaluated against the total number of ORIC Pharmaceuticals shares, or, against the total number of tradable ORIC Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ORIC Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 ORIC Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1205% of the tradable shares (for every 100,000 tradable ORIC Pharmaceuticals shares, roughly 121 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against ORIC Pharmaceuticals.

Find out more about how you can short ORIC Pharmaceuticals stock.

ORIC Pharmaceuticals share dividends

We're not expecting ORIC Pharmaceuticals to pay a dividend over the next 12 months.

ORIC Pharmaceuticals overview

ORIC Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Astellas Pharma, Inc. ; Voronoi, Inc.

Frequently asked questions

What percentage of ORIC Pharmaceuticals is owned by insiders or institutions?
Currently 1.049% of ORIC Pharmaceuticals shares are held by insiders and 96.57% by institutions. How many people work for ORIC Pharmaceuticals?
Latest data suggests 70 work at ORIC Pharmaceuticals. When does the fiscal year end for ORIC Pharmaceuticals?
ORIC Pharmaceuticals's fiscal year ends in December. Where is ORIC Pharmaceuticals based?
ORIC Pharmaceuticals's address is: 240 East Grand Avenue, South San Francisco, CA, United States, 94080 What is ORIC Pharmaceuticals's ISIN number?
ORIC Pharmaceuticals's international securities identification number is: US68622P1093 What is ORIC Pharmaceuticals's CUSIP number?
ORIC Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 68622P109